Navigation Links
MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Date:7/31/2012

MOUNTAIN VIEW, Calif., July 31, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today that it intends to offer and sell shares of its common stock in an underwritten public offering.  MAP Pharmaceuticals expects to grant the underwriters a 30-day option to purchase an additional 15% of the shares of common stock to be sold in the proposed offering.  All of the shares to be sold in the proposed offering will be sold by MAP Pharmaceuticals.  MAP Pharmaceuticals intends to use the proceeds from the proposed offering for general corporate purposes and commercialization activities for LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine.  The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

BofA Merrill Lynch is acting as the sole book-running manager for the proposed offering. 

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective.  A preliminary prospectus supplement relating to the offering has been filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from the offices of BofA Merrill Lynch, 222 Broadway, 7th Floor, New York, NY 10038, Attn: Prospectus Department, or email dg.prospectus_requests@baml.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About MAP Pharmaceuticals

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. 

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to our expectations regarding the completion of the proposed public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not we will be able to raise capital through the sale of shares of common stock, the final terms of the proposed offering, market and other conditions, the satisfaction of customary closing conditions related to the proposed public offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that we will be able to complete the proposed public offering on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to the proposed offering, MAP Pharmaceuticals and our business can be found under the heading "Risk Factors" in our most recent Form 10-Q filed with the SEC, in other filings that we periodically make with the SEC, and in the preliminary prospectus supplement related to the proposed offering to be filed with the SEC on the date hereof. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

CONTACT: Christopher Y. Chai, Sr. Vice President and Chief Financial Officer of MAP Pharmaceuticals, Inc., (650) 386-3107; or media, Lisa Borland, (650) 386-3122, lborland@mappharma.com.

Copyright (C) 2012 PR Newswire. All rights reserved


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
3. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
4. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
6. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
7. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
8. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
9. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
10. WuXi PharmaTech Announces Third-Quarter 2011 Results
11. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 22, 2017 Scientists propose in Nature ... damage in Gaucher and maybe other lysosomal storage diseases ... costs than current therapies. An international research ... , which also included investigators from the University of ... data Feb. 22. The study was conducted in mouse ...
(Date:2/22/2017)... Dublin - Research and Markets has announced ... Type, By Application, By End User, By Region, By Country: Opportunities ... ... is forecasted to grow at a CAGR of 11.33% during 2016-2021. ... protection market is driven by the surging demand for less toxic ...
(Date:2/22/2017)... DIEGO , Feb. 22, 2017  Creative ... expansion of its translational research program using its ... of laboratory facilities in San Diego.  The Company ... BioLabs facility, a biotechnology incubator sponsored by the ... In November 2016, the Company obtained an ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... VTX-1 Liquid Biopsy System , a fully automated benchtop system for collecting intact ... VTX-1 is being launched at the Molecular Medicine Tri Conference (Tri-Con) Annual Meeting ...
Breaking Biology Technology:
(Date:2/22/2017)... With the biometrics market to exceed ... technologies that innovative and agile startups must incorporate ... the changing competitive landscape: multifactor authentication (MFA), point-of-sale ... "Companies can no longer afford to cut ... Dimitrios Pavlakis , Industry Analyst at ABI Research. ...
(Date:2/21/2017)... Ore. , Feb. 22, 2017  IBM (NYSE: ... (Avamere Health Services, Infinity Rehab, Signature Hospice, Home Health, ... will apply the power of IBM cognitive computing to ... centers. By analyzing data streaming from sensors in senior ... and environmental conditions, and obtain deeper learnings into the ...
(Date:2/21/2017)... 21, 2017 Der weltweite Biobanking-Sektor ... Nach einem Gespräch mit mehr als 50 Vertretern aus verschiedenen ... überwinden gilt, um diese Prognose zu realisieren. ... Zu ... der finanziellen Mittel für die Biobank, die Implementierung Zeit ...
Breaking Biology News(10 mins):